Biocon DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.87×	0.82×	0.76×	0.81×	0.60×
	0.32×	0.30×	1.28×	0.93×	0.76×
	8.6%	8.9%	9.7%	11.7%	12.5%
	0.28×	0.28×	0.27×	0.27×	0.09×
	1.74×	1.74×	2.12×	2.22×	2.31×
	1.2%	1.1%	5.4%	5.3%	1.2%
	1.4%	1.4%	4.9%	5.4%	3.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

BIOCON₹351.90

Biocon Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA DRREDDY SYNGENE MANKIND GLENMARK LAURUSLABS ALKEM LUPINMcap ₹57,043 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.60	0.81	0.76	0.82	0.87
Interest Burden (Pretax/EBIT) ×	0.76	0.93	1.28	0.30	0.32
EBIT Margin %	12.52	11.72	9.69	8.85	8.59
Asset Turnover ×	0.09	0.27	0.27	0.28	0.28
Financial Leverage (Assets/Equity) ×	2.31	2.22	2.12	1.74	1.74
ROE (5-step product, year-end total equity) %	1.20	5.27	5.37	1.06	1.17
ROE (owners' profit / average owners' equity) %	3.52	5.43	4.89	1.39	1.39

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.